20Med Therapeutics

Veja o organograma con seus 6 executivos principais

Biografias mais buscadas da 20Med Therapeutics

• Michiel Lodder, Chief Executive Officer
• Michel Baijot, Director
• Tom Schwarz, Chairman of the Board

Recentes movimentos de executivos em 20Med Therapeutics

• Hugo Fry, ingressou na Companhia como Chief Business Officer  (Notícia publicada em 29 de novembro de 2023).

Criar um alerta
para seguir os movimentos de executivos da 20Med Therapeutics.

20Med Therapeutics possui 2.273 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Adaptive Phage Therapeutics (Estados Unidos).

Popular M&A news in Biotecnologia

• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (publicado em 16 de abril de 2024).
• Nurix Therapeutics acaba de anunciar uma arrecadação de fundos de 175 milhões de dólares. (publicado em 13 de abril de 2024).
• Nuvation Bio has announced the acquisition of AnHeart  (publicado em 12 de abril de 2024).

Outros contatos sugeridos na indústria do Biotecnologia

• Vik Bajaj - Director da Interline Therapeutics
• Ali Behbahani - Non-Executive Director da Adaptimmune Therapeutics
• Khalil Barrage - Interim Chairman of the Board da Sensorion

Saiba mais sobre a indústria do Biotecnologia >

Últimos comunicados de imprensa de 20Med Therapeutics

• 20Med Therapeutics and Touchlight to collaborate on novel vaccine delivery platform project
• 20Med Therapeutics and CEPI Sign Agreement to Advance ThermoStable Vaccines Technology
• 20Med Therapeutics started research into mRNA vaccines against variants of the SARS-CoV-2 Coronavirus
• 20Med Therapeutics to Participate in the New Cancer Research Consortium Oncode-PACT
• 20Med Therapeutics appoints Allard Kaptein to Supervisory Board | 20Med
• 20Med Therapeutics secures new financing for accelerated development of the 20Med Nanogel technology for the delivery of RNA therapeutics | 20Med
• 20Med Therapeutics has an open PhD position in the ITN CARTHAGO program aimed at developing non-viral gene therapy for the treatment of osteoarthritis. | 20Med
• 20Med Therapeutics expands its R&D team at the Leiden BioScience Park in The Netherlands  | 20Med
• News | 20Med
• New Horizon 2020 Project B-SMART Develops RNA-based Therapy for Neurodegenerative Diseases. | 20Med
• View more press releases Close

Redes sociais sobre 20Med Therapeutics

• 20Med Therapeutics na Wikipedia, Google News e Yahoo Finance
• 20Med Therapeutics na LinkedIn, Twitter e YouTube

Contate seus executivos por e-mail agora, incluindo Michiel Lodder

Ligue para a 20Med Therapeutics em +31 53...

Veja o organograma

Register to receive your alert

Relatório um erro